ABSTRACT The influence of long-term treatment with amiodarone on exercise hemodynamics and on left ventricular relaxation was studied prospectively in patients with hypertrophic cardiomyopathy. Rest-exercise hemodynamics (n = 9) and echocardiographic relaxation indexes (isovolumic relaxation time, dPW/dt) (n = 11) were measured in control conditions and after 5 weeks of oral amiodarone treatment (600 mg daily first week, 400 mg daily second week, 200 mg daily afterwards). Long-term amiodarone treatment in patients at rest caused a significant drop in heart rate from 80 + 1 1 to 75 + 11 beats/min (p < .05), a rise in mean pulmonary artery pressure from 19 + 7 to 25 ± 10 mm Hg (p < .02), and a rise in mean pulmonary capillary wedge pressure from 11 ± 4 to 17 ± 8 mm Hg (p < .05). Systemic arterial pressure, cardiac output, and systemic vascular resistance remained unaltered. Exercise tolerance assessed by serial supine bicycle stress testing was reduced in six of nine patients. Amiodarone treatment caused a significant rise in pulmonary capillary wedge pressure from 22 ± 8 to 37 ± 9 mm Hg (p < .001) at the highest identical workloads and from 26 ± 10 to 37 9 (p < .005) at maximal symptom-limited workloads. Similarly, mean pulmonary artery pressure rose from 37 + 15 to 51 ± 18 mm Hg (p < .01) at highest identical workloads and from 42 ± 19 to 51 ± 18 mm Hg (p < .01) at maximal symptom-limited workloads. There were no significant differences at maximal exercise level in heart rate, systemic arterial pressure, cardiac output, or exercise factor. Echocardiographic studies performed before and during long-term amiodarone treatment revealed no change in isovolumic relaxation time, end-diastolic or end-systolic posterior wall thickness, and peak posterior wall thinning rate. A negative inotropic action of amiodarone could explain the worsened rest and exercise hemodynamics observed during long-term treatment of patients with hypertrophic cardiomyopathy. Echocardiographic relaxation indexes remained unaltered despite the elevated left ventricular filling pressures. This finding could suggest a deleterious effect of amiodarone on myocardial inactivation, possibly similar in mechanism to the depressed myocardial inactivation observed in hypothyroidism. Circulation 74, No. 3, 544-554, 1986. ,3-ADRENERGIC blocking agents, calcium channelblocking agents, and disopyramide have been variably successful for the relief of symptoms in patients with hypertrophic cardiomyopathy. fl-Blockade was associated with amelioration of dyspnea or angina' 2 but failed to alter the primary cardiomyopathic process.
negative inotropic action,'8 which decreased outflow tract gradients, thereby reducing symptoms in some patients but not in all of them. 3 The benzofuran derivative amiodarone was successfully used for the treatment of ventricular tachycardias,'9 and the drug has been proposed to improve survival in patients with hypertrophic cardiomyopathy suffering from high-grade ventricular arrhythmia when compared with conventional antiarrhythmic agents. 20 Moreover, long-term amiodarone treatment was recently reported to improve cardiac symptoms2' and to increase exercise capacity in patients with hypertrophic cardiomyopathy.22 These effects were accompanied by an improvement of rapid left ventricular filling on radionuclide left ventricular angiograms. 23 The hemodynamic effects of long-term amiodarone therapy as well as its influence on left ventricular echocardiographic relaxation indexes have not yet been reported in patients with hypertrophic cardiomyopathy. We therefore undertook a prospective study to investigate the influence of long-term amiodarone treatment on rest and exercise hemodynamics as well as on echocardiographic left ventricular relaxation indexes in patients with hypertrophic cardiomyopathy.
Methods
Patients. Eleven patients (four women, seven men) (ages 39 to 81 years, mean 57) with clinical, echocardiographic, or angiographic evidence of hypertrophic cardiomyopathy were studied prospectively. Hypertrophic cardiomyopathy was defined by the presence of a hypertrophied nondilated left ventricle in the absence of a cardiac or systemic disease that itself could produce left ventricular hypertrophy. 24 Informed consent was obtained for each patient. Before and during long-term amiodarone treatment, nine patients (four women, five men) underwent both hemodynamic studies and echocardiographic investigations, whereas two patients underwent only sequential echocardiographic studies. Patient characteristics, predominant symptoms, functional class (NYHA), distribution of left ventricular hypertrophy, and presence and severity of systolic anterior motion (SAM) are summarized in table 1. At the time of the control study, three patients were in functional class I (NYHA), six patients were in class II, and two patients were in class III. Based on echocardiographic or angiographic findings, the distribution of left ventricular hypertrophy was classified as septal, apical, or concentric.3' 25, 26 Patients with septal left ventricular hypertrophy (patients 3, 4, 6, 8, 9 , and 1 1) belonged to type III 8 , inducible gradient > 30 mm Hg). Selective coronary arteriography was performed before the control study in patients with angina (patients 1, 3, 8, and 1 1) and revealed no significant coronary artery stenoses (coronary artery luminal diameter narrowing < 50%). Patients with abnormal thyroid function tests, detectable thyroid antibodies, or restrictive lung disease were excluded from the study. On a 24 hr electrocardiographic monitoring performed less than 1 month before the control study, all patients were in sinus rhythm with no or low grade ventricular arrhythmias. The absence of supraventricular arrhythmias or high-grade ventricular arrhythmias avoids the confounding influence of improved arrhythmia control on hemodynamic and echocardiographic measurements during long-term amiodarone treatment. All medications were stopped 48 hr before the control hemodynamic and/or echocardiographic study and all other medications were withheld during the period of the oral amiodarone drug regimen, except in one patient, whose antiepileptic drugs were continued throughout. After the control investigations, all patients were started on oral amiodarone (600 mg daily during the first week, 400 mg daily during the second week, and 200 mg daily afterwards as a maintenance dose). Repeat hemodynamic and echocardiographic studies were performed after 5 weeks of oral amiodarone treatment. At the time of the second 546 systemic vascular study there was a significant prolongation of the corrected QT interval from 442 + 37 to 494 + 23 msec (n = 1 1; p < .05), which is consistent with the myocardium being impregnated by amiodarone as a result of the long-term drug regimen. 30 Despite the low dose of amiodarone during maintenance treatment and the short observation period, most patients developed a photosensitive rash. There was no toxic effect on thyroid function, no pulmonary fibrosis, and no drug-induced hepatitis. After the repeat hemodynamic or echocardiographic study, the drug was discontinued in all patients.
Hemodynamic studies. Right heart cardiac catheterizations were performed by brachial vein cutdown or by the percutaneous jugular vein approach. A thermodilution balloon-tipped catheter was advanced into the pulmonary artery and a small Teflon catheter was introduced in the brachial or radial artery for continuous systemic arterial pressure monitoring. Systemic arterial pressure, pulmonary capillary wedge pressure, pulmonary artery pressure, and right atrial pressure were measured by HP 1 290A transducers, which were referenced to atmosphere at the midchest level. The pressure signals and the three bipolar standard leads of the electrocardiogram were recorded on a Gould ES 1000 multichannel recorder. At rest, hemodynamic recordings of right atrial, pulmonary capillary wedge. pulmonary arterial, and systemic arterial pressures were obtained. During exercise, pulmonary capillary wedge, pulmonary arterial, and systemic arterial pressures were recorded at 1 min intervals. Cardiac output measurements at rest or in the last minute of exercise were performed by the thermodilution technique (Edwards Laboratories, 9520 A Cardiac Output Computer; average of at least three values) or by the Fick principle (oxygen content of expired air continuously measured by Oxylog oximeter).31 At rest and at maximal exercise, level pulmonary artery and arterial blood samples were obtained and oxygen saturations were determined with an OSM2 Hemoximeter (Radiometer Copenhagen). All patients underwent supine bicycle exercise stress testing on a Monark ergometer with stepwise (3 min interval) increment (12.5 W) of workload while pedaling at a fixed pace of 50 rounds/min. Initial workloads and the exercise protocol were identical in both exercise tests. The exercise factor (table 3) was calculated as the ratio of the exerciseinduced increment of cardiac output to the increment of oxygen consumption (normal value 6.0).32 Pressure signals were digi- (A2), and single-lead electrocardiogram were recorded at a paper speed of 100 mm/sec in control conditions and after 5 weeks of long-term amiodarone administration (figure 3). The left ventricular isovolumic relaxation time (IVRT) (table 4, figure 3 ) was calculated as the interval (msec) between the first high-frequency components of the aortic valve closure sound (vertical line at A2 in figure 3 ) and the opening point of the mitral valve leaflets on the mitral valve echocardiogram. Posterior wall endocardium and epicardium of the left ventricular cavity echocardiogram were digitized every 5 msec from the peak of the R wave of the electrocardiogram to the peak of the R wave of the subsequent beat and were analyzed with an Apple M 0001 WP 512K computer. A sixth-order polynomial was fitted to the diastolic portion of the posterior wall thickness data for determination of the first derivative to calculate peak posterior wall thinning rate (dPW/dt, mm/sec) (table 4). The interobserver, intraobserver, day-to-day, and cycle-to-cycle variability coefficients for IVRT and dPW/dt determined by this computerassisted analysis were found to be 5% or less.13 ' 33 Statistical analysis. Hemodynamic data: exercise. Exercise hemodynamic variables were recorded under control conditions (n = 9) and after 5 weeks of oral amiodarone treatment (n = 7) (see table 3 ). Two patients could no longer exercise during amiodarone treatment because of markedly increased PCW at rest, which caused orthopnea when the legs were raised to strap the feet to the bicycle. During amiodarone treatment, the remaining seven patients exercised at the same workloads as in the control run. For three of them, the duration of exercise was unaltered, whereas four of them stopped exercising earlier than in the control run. Because of the reduced exercise tolerance during amiodarone treatment in four patients, exercise data recorded before and during amiodarone treatment were compared in two ways. The 
Discussion
In recent years, amiodarone has received widespread attention as a valuable therapeutic adjunct to the medical management of patients with hypertrophic cardiomyopathy. The drug has been shown to be effective as an antiarrhythmic agent for the treatment of ventricular arrhythmias,'9 and when compared with conventional class I antiarrhythmic agents it was shown to improve survival in patients with hypertrophic cardiomyopathy.20 Left ventricular function studies during long-term amiodarone treatment have been performed with serial radionuclide angiograms, which documented unaltered ejection fraction and left ventricular filling indexes in patients with hypertrophic cardiomyopathy34 and in patients with congestive car- 23 In the present study on the influence of long-term amiodarone treatment in patients with hypertrophic cardiomyopathy, opposite results were obtained: amiodarone had a negative effect on rest and exercise hemodynamics, whereas echocardiographic relaxation indexes remained unaltered. The severity and nature of symptoms, the stress testing protocol, and the presence of arrhythmias could account for the observed discrepancies in amiodarone's effect on left ventricular function in patients with hypertrophic cardiomyopathy. The cause of symptoms in hypertrophic cardiomyopathy is thought to be multifactorial: decreased diastolic distensibility with blunted rapid left ventricular filling, the occurrence and magnitude of an outflow tract gradient, and the presence of myocardial ischemia. Moreover, certain pathophysiologic mechanisms such as myocardial ischemia and decreased left ventricular distensibility interact.33' 3 Because of the multifactorial origin of symptoms, the benefit of a therapeutic intervention depenas on the prevailing symptom and the severity of symptoms in the study group. When most patients in a study population stop exercising because of angina, an agent like amiodarone, which possesses mild anti-ischemic and a-X3-blocking properties, might cause an overall symptomatic benefit. Such effect is unlikely to occur when dyspnea is the predominant limiting symptom during exercise. In such an instance a drug inat fails to correct left ventricular diastolic properties is unlikely to be of symptomatic benefit. In our study, eight of nine patients had no or mild symptoms on clinical evaluation at the time of the control studies and most of them were limited during exercise testing by dyspnea (table 1) . A different therapeutic result could be obtained in a study population that is more severely symptomatic and whose predominant symptom is angina.
In the present study, all patients underwent supine bicycle exercise stress testing. In previous reports22 23 on exercise tolerance during long-term amiodarone treatment in patients with hypertrophic cardiomyopathy, a treadmill exercise test was used. During a supine bicycle exercise test there is a larger increase in venous return. Whenever there is a pathologic response to exercise, left ventricular filling pressures will therefore be augmented more rapidly during su-50 C REST pine bicycle exercise stress testing, with the earlier occurrence of dyspnea and a concomitant reduction in exercise tolerance. This abnormal exercise physiology will be more evident when abnormal diastolic properties are prominent, as in hypertrophic cardiomyopathy. In fact, the present and similar studies9 showed increased PCW during supine bicycle exercise stress testing in patients with hypertrophic cardiomyopathy with normal exercise tolerance and minimal or no symptoms. In supine bicycle exercise stress testing, there is improved exercise tolerance during therapy with verapamil, probably because of improved diastolic properties, but not during therapy with propranolol. ,3-blocking drugs on left ventricular diastolic properties in patients with hypertrophic cardiomyopathy.5 An elevation of left ventricular filling pressures causes premature opening of the mitral valve and shortens IVRT. During long-term amiodarone treatment IVRT remained unaltered despite elevated PCW. This finding suggests a slower decay of isovolumic pressure as a result of long-term amiodarone treatment. In previous studies in normal subjects there was no correlation between heart rate at rest over a range varying from 44 to 99 beats/min and peak left ventricular filling rate. 38 The decrease in heart rate (from 80 to 75 beats/min; p < .05) observed in our study during long-term amiodarone treatment falls within this range.
Echocardiographic indexes of left ventricular filling such as peak filling rate or dPW/dt were shown to be dependent on shortening fraction`or on extent of wall thickening.39 Other investigators using radionuclide left ventricular angiograms normalized left ventricular volumes by end-diastolic volume.'2' 37 In the present study there was no significant change during long-term amiodarone treatment in the extent of wall thickening or end-diastolic wall thickness. On the other hand, left ventricular filling pressure (measured as mean PCW) was significantly elevated during long-terrn amiodarone treatment. In experiments with isolated cardiac muscle, lengthening velocity was a function of end-systolic length and lengthening load.4' Under controlled loading conditions such as those that occur in isolated muscle experiments, lengthening load equals diastolic load and determines end-diastolic dimension in accordance with the passive length-tension characteristics of the muscle preparation. Therefore lengthening load and end-diastolic dimension are considered to be interchangeable as determinants of muscle lengthening. However, when diastolic load varies, as always occurs during filling of the intact heart, the same relationship no longer holds. In such instances wall stress at peak filling rate is the determinant of myocardial lengthening and not end-diastolic dimension. Wall stress itself is determined both by filling pressure and by instantaneous left ventricular dimensions. In the present study, during long-term amiodarone treatment left ventricular dimensions were comparable to control data but filling pressures were significantly elevated. Therefore wall stress during filling was probably elevated. Under conditions of elevated diastolic wall stress during longterm amiodarone treatment, peak posterior wall thinning rate should increase if myocardial inactivation and end-systolic dimensions remain unaltered. 33 In the present study, however, we observed no change in peak posterior wall thinning rate despite elevated diastolic left ventricular filling pressures and unaltered end-systolic wall thickness during long-term amiodarone therapy. This result could imply a worsening of myocardial inactivation by amiodarone, whose effect on left ventricular filling is partially corrected by the elevated left ventricular filling pressures and therefore results in unaltered echocardiographic left ventricular filling indexes.
There are no experimental data concerning the influence of long-term amiodarone on isolated cardiac muscle relaxation. The drug's intrinsic properties are suggestive of a hypothyroid state of the heart, e.g., sinus bradycardia through sinus node depression, reduced myocardial oxygen demand independent of sinus bradycardia, and prolongation of the corrected QT interval.42 43 In hypothyroid heart disease, an impairment of left ventricular relaxation has previously been demonstrated" and explained by deficient calcium reuptake of the sarcoplasmic reticulum. This mechanism also accounts for slow striated muscle relaxation, which causes the characteristic slow tendon reflexes of hypothyroidism. A hypothyroid state of the heart induced by long-term amiodarone treatment could explain a depressant effect of amiodarone on myocardial inactivation.
Amiodarone exhibits a noncompetitive blockade of both a-and ,3-adrenergic receptors.`Its alphalytic action could lead to peripheral vasodilatation, which was observed after short-term intravenous administration in some studies46 but not confirmed by others.36 During long-term administration no significant change in systemic vascular resistance was demonstrated in patients with coronary disease36 or in the present study in patients with hypertrophic cardiomyopathy. However, a progressive drop in systemic vascular resistance was observed in patients with congestive failure from chronic Chagas disease.7 Such a vasodilatory effect warrants caution, especially in patients with an obstructive form of hypertrophic cardiomyopathy. In the present study, two patients with severe SAM had evidence of an earlier onset of mitral leaflet-septal contact on the mitral valve echocardiogram during long-term amiodarone treatment (table 1, patients 6 and 11). An earlier onset of mitral leaflet-septal contact argues in favor of an increment in outflow tract gradient, which could also affect left ventricular isovolumic relaxation by altering end-systolic loading conditions .' Definitive evidence for a change in magnitude of the outflow tract gradient during long-term amiodarone treatment requires repeat left-heart cardiac catheterization, which was not performed in this study. Apart from its alphalytic properties, amiodarone also blocks 3-adrenergic receptors. The effects of /8-blockade on exercise tolerance and diastolic properties in patients with hypertrophic cardiomyopathy remain controversial.2 5, 6 9 In summary, long-term treatment with amiodarone in patients with hypertrophic cardiomyopathy caused a small but significant increase in left ventricular filling pressures at rest. Exercise tolerance assessed by repeat supine bicycle stress testing was reduced in most patients because of higher PCW pressures at identical workloads. The worsened rest and exercise hemodynamics are consistent with a negative inotropic action of amiodarone. Echocardiographic relaxation indexes such as IVRT and dPW/dt remained unaltered during long-term amiodarone treatment despite an elevation of left ventricular filling pressures. This finding suggests an impairment of myocardial inactivation induced by long-term amiodarone treatment. Such impairment is possibly similar in mechanism to the depressed myocardial inactivation observed in hypothyroidism.
We gratefully acknowledge the technical assistance of Jan Stockbroeckx, Bart Couck, Freddy De Pauw, and Marcel De Meester.
